Mark Frakes
Tanzania
Research Article
c-Met: A Potential Target for Current Non-Small-Cell Lung Cancer Therapeutics
Author(s): Amanda Stone, Supriya Rajanna, Ichwaku Rastogi, Joe Cruz, Kymberly Harrington, Kory Blank, Mark Frakes and Neelu PuriAmanda Stone, Supriya Rajanna, Ichwaku Rastogi, Joe Cruz, Kymberly Harrington, Kory Blank, Mark Frakes and Neelu Puri
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In early stages of NSCLC tumor development (stage I/II), surgical resection is often performed; however, when the cancer becomes metastatic, chemotherapy is most commonly implemented. Due to the fact that traditional chemotherapies result in adverse and cytotoxic effects on healthy cells in addition to NSCLC cells, targeted therapeutics have been extensively developed over recent years to combat the disease. These targeted therapies include small molecule inhibitors and monoclonal antibodies (MAbs), some of which are used as first-line treatments for NSCLC patients. Several inhibitors against the mesenchymal-epithelial transition factor (c-Met), and its ligand hepatocyte growth factor (HGF), have shown promising results in NSCLC clinical trials. For example, crizotinib, a multi-kinase inhibitor has been approved b.. View More»
